JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB265815

Human C12orf44 knockout HeLa cell line

Be the first to review this product! Submit a review

|

(0 Publication)

ATG101 KO cell line available to order. KO validated by. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon 3 and 1 bp insertion in exon 3 and 2 bp deletion in exon 3.

View Alternative Names

ATGA1_HUMAN, Atg13-interacting protein, Autophagy-related protein 101, C12orf44, Chromosome 12 open reading frame 44, FLJ11773, OTTHUMP00000241687, OTTHUMP00000241688, OTTHUMP00000241689

3 Images
Sanger Sequencing - Human C12orf44 knockout HeLa cell line (AB265815)
  • Sanger seq

Unknown

Sanger Sequencing - Human C12orf44 knockout HeLa cell line (AB265815)

Allele-3 : 1 bp insertion in exon 3.

Sanger Sequencing - Human C12orf44 knockout HeLa cell line (AB265815)
  • Sanger seq

Unknown

Sanger Sequencing - Human C12orf44 knockout HeLa cell line (AB265815)

Allele-2 : 1 bp deletion in exon 3.

Sanger Sequencing - Human C12orf44 knockout HeLa cell line (AB265815)
  • Sanger seq

Unknown

Sanger Sequencing - Human C12orf44 knockout HeLa cell line (AB265815)

Allele-1 : 2 bp deletion in exon 3.

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Form

Liquid

form

Knockout validation

Sanger Sequencing

Mutation description

Knockout achieved by using CRISPR/Cas9, 1 bp deletion in exon 3 and 1 bp insertion in exon 3 and 2 bp deletion in exon 3

Disease

Adenocarcinoma

Product details

Recommended control: Human wild-type HeLa cell line (ab255928). Please note a wild-type cell line is not automatically included with a knockout cell line order, if required please add recommended wild-type cell line at no additional cost using the code WILDTYPE-TMTK1.

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

What's included?

{ "values": { "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab265815-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265815 Human C12orf44 knockout HeLa cell line", "number":"AB265815-CMP01" } ] }, "1000000Cellsvial": { "sellingSize": "1000000 Cells/vial", "publicAssetCode":"ab265815-1000000Cells_vial", "assetComponentDetails": [ { "size":"1 x 1000000 Cells/vial", "name":"ab265815 Human C12orf44 knockout HeLa cell line", "number":"AB265815-CMP01", "productcode":"" } ] } } }

Properties and storage information

Gene name
ATG101
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing
Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium

DMEM (High Glucose) + 10% FBS

Cryopreservation medium

Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

ATG101 also known as Autophagy Related Protein 101 is a critical component of the cellular process known as autophagy. This protein has an approximate mass of 289 amino acids making it a modest-sized protein. ATG101 is expressed in various cell types especially in those with high autophagic activity. It mainly resides in the cytoplasm where it participates in the initiation and regulation of autophagosome formation.
Biological function summary

ATG101 plays an essential role in the maintenance and regulation of cellular homeostasis. It is a member of the ULK1 complex partnering with proteins like ULK1 ATG13 and FIP200. This complex is critical for the initiation step of autophagy helping cells respond to nutrient deprivation by recycling cellular components into essential biomolecules. ATG101 stabilizes the ULK1 complex and enhances its kinase activity important for subsequent steps in the autophagy pathway.

Pathways

ATG101 is involved in autophagy and mTOR signaling pathways. The mTOR pathway regulates cell growth and survival while autophagy ensures the degradation of damaged cellular components. ATG101 interacts with proteins ULK1 and mTORC1 to coordinate the inhibition of autophagy under nutrient-rich conditions and its activation during starvation or stress. This modulation enables the cell to adapt to varying environmental conditions by controlling autophagic flux.

ATG101 has implications in cancer and neurodegenerative diseases. Proper autophagic activity regulated by ATG101 prevents the accumulation of damaged proteins which can lead to diseases. Disruptions involving ATG101 or its associated proteins such as ULK1 are often observed in cancer cells where impaired autophagy can lead to unchecked cellular proliferation. Additionally in neurodegenerative diseases like Parkinson's defects in autophagy-related proteins including ATG101 contribute to neuronal cell death and the accumulation of toxic protein aggregates.

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

Product protocols

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com